Akèy › Kansè Poumon ki pa ti selil › Minnesota

Etid klinik pou Kansè Poumon ki pa ti selil nan Minnesota

69 etid pou Kansè Poumon ki pa ti selil ap chèche patisipan nan sit nan Minnesota.

Vil nan Minnesota

Tèks ofisyèl etid la (Anglè)

Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

Sanford Joe Lueken Cancer Center, Bemidji
Minnesota Oncology - Burnsville, Burnsville
Mercy Hospital, Coon Rapids
ak 16 plis

Ap rekriteFaz 3

Laj 18 ak plis · Tout sèks · Mizajou Oct 2, 2026 · NCT04267848

A Study of Targeted Post-Surgery Radiation Therapy for Non-Small Cell Lung Cancer With Remaining Lymph Node Cancer After Treatment

Sanford Joe Lueken Cancer Center, Bemidji
Essentia Health Saint Joseph's Medical Center, Brainerd
Essentia Health - Deer River Clinic, Deer River
ak 6 plis

Ap rekriteFaz 2

Laj 18 ak plis · Tout sèks · Mizajou Oct 2, 2026 · NCT07293247

Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors

Exelixis Clinical Site #68, Rochester

Ap rekriteFaz 1

Laj 18 ak plis · Tout sèks · Mizajou Oct 1, 2026 · NCT05176483

Cemiplimab and Fianlimab Before Surgery for the Treatment of Stage IB-IIIB Non-Small Cell Lung Cancer

Mayo Clinic in Rochester, Rochester

Ap rekriteFaz 2

Laj 18 ak plis · Tout sèks · Mizajou Oct 1, 2026 · NCT06918132

A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors

Health Partners Frauenshuh Cancer Center, Saint Louis Park
Health Partners Cancer Center at Regions Hospital, Saint Paul

Ap rekriteFaz 2

Laj 18 ak plis · Tout sèks · Mizajou Oct 1, 2026 · NCT06172478

A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan, Monotherapy or in Combination With Osimertinib, Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer

HealthPartners Cancer Research Center /ID# 277339, Saint Louis Park

Ap rekriteFaz 2/3

Laj 18 ak plis · Tout sèks · Mizajou Oct 1, 2026 · NCT07155187

Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial

Sanford Joe Lueken Cancer Center, Bemidji
Essentia Health Saint Joseph's Medical Center, Brainerd
Mercy Hospital, Coon Rapids
ak 12 plis

Ap rekriteFaz 3

Laj 18 ak plis · Tout sèks · Mizajou Oct 1, 2026 · NCT06498635

A Platform Study in Non-Small Cell Lung Cancer (NSCLC)

Research Site, Rochester

Ap rekriteFaz 1/2

Laj 18 ak plis · Tout sèks · Mizajou Oct 1, 2026 · NCT06996782

A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)

Minnesota Oncology Hematology, Maple Grove
Allina Health Cancer Institute - Abbott Northwestern Hospital, Minneapolis

Ap rekriteFaz 3

Laj 18 ak plis · Tout sèks · Mizajou Sep 30, 2026 · NCT07361497

Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations

St. Luke'S /ID# 273344, Duluth
Mayo Clinic-Rochester /ID# 274512, Rochester

Ap rekriteFaz 1/2

Laj 18 ak plis · Tout sèks · Mizajou Sep 29, 2026 · NCT06772623

A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)

Minnesota Oncology Hematology, PA, Burnsville
Allina Health Cancer Institute - Mercy Hospital, Coon Rapids
Minnesota Oncology Hematology, PA, Coon Rapids
ak 7 plis

Ap rekriteFaz 3

Laj 18 ak plis · Tout sèks · Mizajou Sep 28, 2026 · NCT07144280

A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)

Allina Health Cancer Institute - Abbott Northwestern Hospital ( Site 0027), Minneapolis
Mayo Clinic - Rochester ( Site 0073), Rochester

Ap rekriteFaz 3

Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT06312137

Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Minnesota Oncology Hematology, P.A., Burnsville
Minnesota Oncology Hematology, P.A., Chaska
Allina Health Cancer Institute - Mercy Hospital, Coon Rapids
ak 7 plis

Ap rekriteFaz 3

Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT07222566

Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing

Mayo Clinic Rochester, Rochester

Ap rekriteEtid obsèvasyon

Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT04981119

This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.

Minnesota Oncology Hematology, PA, Burnsville
Minnesota Oncology Hematology PA, Coon Rapids
M Health Fairview Cancer Clinic-Edina, Edina
ak 10 plis

Ap rekriteFaz 3

Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT06758401

A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

University Of Minnesota, Minneapolis
Mayo Clinic Rochester, Rochester

Ap rekriteFaz 2

Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT06667076

A Study to Investigate Ubamatamab With and Without Marlotamig (REGN7075) in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)

Mayo Clinic, Rochester

Ap rekriteFaz 2

Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT07154290

Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)

Allina Health Cancer Institute - Abbott Northwestern Hospital ( Site 0115), Minneapolis
Mayo Clinic - Rochester ( Site 0148), Rochester

Ap rekriteFaz 3

Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT06170788

Pan-tumor MRD Study

Mayo Clinic, Rochester

Ap rekriteEtid obsèvasyon

Laj 18 ak plis · Tout sèks · Mizajou Sep 24, 2026 · NCT06605404

Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change

Minnesota Oncology - Burnsville, Burnsville
Cambridge Medical Center, Cambridge
Minnesota Oncology Hematology PA-Chaska, Chaska
ak 23 plis

Ap rekriteFaz 2

Laj 18 ak plis · Tout sèks · Mizajou Sep 24, 2026 · NCT03191149

An Adjuvant Study to Evaluate SMS001 (Paclitaxel) in Non-Small Cell Lung Cancer

Mayo Clinic, Rochester

Ap rekriteFaz 2

Laj 18 a 80 · Tout sèks · Mizajou Sep 24, 2026 · NCT06693336

A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)

Research Site, Duluth
Research Site, Rochester

Ap rekriteFaz 3

Laj 18 ak plis · Tout sèks · Mizajou Sep 18, 2026 · NCT06692738

Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1

Clinical Study Sites, Duluth
Clinical Study Site, Minneapolis
Clinical Study Site, Saint Paul

Ap rekriteFaz 3

Laj 18 ak plis · Tout sèks · Mizajou Sep 18, 2026 · NCT06767514

Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer

Minnesota Oncology and Hematology PA, Minneapolis

Ap rekriteFaz 1/2

Laj 18 ak plis · Tout sèks · Mizajou Sep 18, 2026 · NCT05267626

Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies

Masonic Cancer Center University of Minnesota, Minneapolis

Ap rekriteFaz 1/2

Laj 18 ak plis · Tout sèks · Mizajou Sep 16, 2026 · NCT05786924

Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7

USOR - Minnesota Oncology - Burnsville, Burnsville
Local Institution - 007-589A, Edina

Ap rekriteFaz 2/3

Laj 18 ak plis · Tout sèks · Mizajou Sep 16, 2026 · NCT04613596

Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer

Mayo Clinic, Rochester

Ap rekriteFaz 3

Laj 18 ak plis · Tout sèks · Mizajou Sep 15, 2026 · NCT06899126

ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation

Mayo Clinic (Rochester), Rochester

Ap rekriteEtid obsèvasyon

Laj 18 ak plis · Tout sèks · Mizajou Sep 14, 2026 · NCT05059444

A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)

Mayo Clinic, Rochester

Ap rekriteFaz 2

Laj 18 ak plis · Tout sèks · Mizajou Sep 10, 2026 · NCT04302025

A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

Allina Health Cancer Institute - Abbott Northwestern Hospital, Minneapolis
HealthPartners Cancer Research Center, Saint Paul

Ap rekriteFaz 3

Laj 18 ak plis · Tout sèks · Mizajou Sep 8, 2026 · NCT06119581

A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors

Mayo Rochester, Rochester

Ap rekriteFaz 1

Laj 18 ak plis · Tout sèks · Mizajou Sep 4, 2026 · NCT07361562

Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations

Research Site, Rochester

Ap rekriteFaz 3

Laj 18 ak plis · Tout sèks · Mizajou Sep 4, 2026 · NCT07291037

Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]

Allina Health Cancer Institute - Abbott Northwestern Hospital ( Site 0146), Minneapolis

Ap rekriteFaz 3

Laj 18 ak plis · Tout sèks · Mizajou Sep 3, 2026 · NCT06422143

FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors

University of Minnesota Masonic Cancer Center, Minneapolis

Ap rekriteFaz 1

Laj 18 ak plis · Tout sèks · Mizajou Sep 2, 2026 · NCT07216105

A Study of Tolododekin Alfa (ANK-101) in Combination With an Anti-PD-1/PD-L1 Antibody in Participants With Advanced Non-Small Cell Lung Cancer

Mayo Clinic, Rochester

Ap rekriteFaz 1

Laj 18 ak plis · Tout sèks · Mizajou Sep 2, 2026 · NCT07027514

Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion

Mayo Clinic, Rochester

Ap rekriteFaz 1

Laj 18 ak plis · Tout sèks · Mizajou Sep 2, 2026 · NCT05245500

A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors

Mayo Clinic - Rochester, Rochester

Ap rekriteFaz 1

Laj 18 ak plis · Tout sèks · Mizajou Sep 2, 2026 · NCT04913285

Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer

Research Site, Saint Paul

Ap rekriteFaz 3

Laj 18 ak plis · Tout sèks · Mizajou Aug 26, 2026 · NCT06350097

A Clinical Study to Investigate the Efficacy and Safety of an Investigational Combination Therapy With BNT324 and BNT327 in Patients With Advanced Lung Cancer

Mayo Clinic-Rochester, Rochester

Ap rekriteFaz 1/2

Laj 18 ak plis · Tout sèks · Mizajou Aug 26, 2026 · NCT06892548

A Tool for Improving the Shared Decision-making Process in Patients With Non-small Cell Lung Cancer

Mayo Clinic in Rochester, Rochester

Ap rekriteVolontè an sante akeyi

Laj 18 ak plis · Tout sèks · Mizajou Aug 20, 2026 · NCT06122064

Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.